PT2332567E - Terapia combinada para o tratamento de distúrbios de deficiência proteica - Google Patents

Terapia combinada para o tratamento de distúrbios de deficiência proteica Download PDF

Info

Publication number
PT2332567E
PT2332567E PT100115989T PT04011598T PT2332567E PT 2332567 E PT2332567 E PT 2332567E PT 100115989 T PT100115989 T PT 100115989T PT 04011598 T PT04011598 T PT 04011598T PT 2332567 E PT2332567 E PT 2332567E
Authority
PT
Portugal
Prior art keywords
combination therapy
protein deficiency
deficiency disorders
treating protein
treating
Prior art date
Application number
PT100115989T
Other languages
English (en)
Inventor
Jian-Qiang Fan
Original Assignee
Sinai School Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sinai School Medicine filed Critical Sinai School Medicine
Publication of PT2332567E publication Critical patent/PT2332567E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nutrition Science (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
PT100115989T 2003-01-31 2004-02-02 Terapia combinada para o tratamento de distúrbios de deficiência proteica PT2332567E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US44413603P 2003-01-31 2003-01-31

Publications (1)

Publication Number Publication Date
PT2332567E true PT2332567E (pt) 2015-09-23

Family

ID=32850826

Family Applications (5)

Application Number Title Priority Date Filing Date
PT110064953T PT2444102E (pt) 2003-01-31 2004-02-02 Terapia combinada para o tratamento de distúrbios de deficiência proteica
PT04707422T PT1589993E (pt) 2003-01-31 2004-02-02 Terapia combinada para o tratamento de distúrbios de deficiência proteica
PT141971978T PT2857036T (pt) 2003-01-31 2004-02-02 Terapia combinada para o tratamento de distúrbios de deficiência proteica
PT100115989T PT2332567E (pt) 2003-01-31 2004-02-02 Terapia combinada para o tratamento de distúrbios de deficiência proteica
PT110065042T PT2441467E (pt) 2003-01-31 2004-02-02 Terapia combinada para o tratamento de transtornos associados a uma deficiência proteica

Family Applications Before (3)

Application Number Title Priority Date Filing Date
PT110064953T PT2444102E (pt) 2003-01-31 2004-02-02 Terapia combinada para o tratamento de distúrbios de deficiência proteica
PT04707422T PT1589993E (pt) 2003-01-31 2004-02-02 Terapia combinada para o tratamento de distúrbios de deficiência proteica
PT141971978T PT2857036T (pt) 2003-01-31 2004-02-02 Terapia combinada para o tratamento de distúrbios de deficiência proteica

Family Applications After (1)

Application Number Title Priority Date Filing Date
PT110065042T PT2441467E (pt) 2003-01-31 2004-02-02 Terapia combinada para o tratamento de transtornos associados a uma deficiência proteica

Country Status (16)

Country Link
US (4) US20040180419A1 (pt)
EP (6) EP2857036B1 (pt)
JP (5) JP5589165B2 (pt)
CN (4) CN102580067A (pt)
BR (1) BRPI0407001A (pt)
CA (3) CA2814767C (pt)
CY (5) CY1116215T1 (pt)
DK (5) DK2444102T3 (pt)
ES (6) ES2541952T3 (pt)
HK (4) HK1158955A1 (pt)
HU (2) HUE027113T2 (pt)
IL (6) IL169562A (pt)
MX (2) MX344587B (pt)
PT (5) PT2444102E (pt)
SI (5) SI1589993T1 (pt)
WO (1) WO2004069190A2 (pt)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040204379A1 (en) * 2000-06-19 2004-10-14 Cheng Seng H. Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
US20020095135A1 (en) * 2000-06-19 2002-07-18 David Meeker Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
US7138262B1 (en) 2000-08-18 2006-11-21 Shire Human Genetic Therapies, Inc. High mannose proteins and methods of making high mannose proteins
PT2444102E (pt) * 2003-01-31 2015-09-17 Sinai School Medicine Terapia combinada para o tratamento de distúrbios de deficiência proteica
FR2861991B1 (fr) 2003-11-07 2008-01-18 Centre Nat Rech Scient Utilisation d'inhibiteurs de glucosidase pour une therapie de la mucoviscidose
US20050256168A1 (en) * 2004-04-28 2005-11-17 Block Timothy M Compositions for oral administration for the treatment of interferon-responsive disorders
EP3441090A1 (en) 2005-05-17 2019-02-13 Amicus Therapeutics, Inc. A method for the treatment of pompe disease using 1-deoxynojirimycin and derivatives
JP2009509913A (ja) 2005-06-08 2009-03-12 アミカス セラピューティックス インコーポレイテッド リソソーム酵素をコードする遺伝子の変異に関連するｃｎｓ障害の治療
JP5364382B2 (ja) * 2006-02-07 2013-12-11 シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド 遊離チオール部分を有するタンパク質の安定化された組成物
PL2787345T3 (pl) 2006-05-16 2016-08-31 Amicus Therapeutics Inc Możliwości leczenia choroby Fabry’ego
ATE555788T1 (de) * 2006-06-23 2012-05-15 Amicus Therapeutics Inc Verfahren zur behandlung neurologischer erkrankungen mittels verstärkung der beta - glucocerebrosidaseaktivität
AU2007277032A1 (en) * 2006-07-27 2008-01-31 University Of Florida Research Foundation, Inc. Opsin stabilizing compounds and methods of use
WO2008013984A2 (en) * 2006-07-27 2008-01-31 University Of Florida Research Foundation, Inc. Compositions and methods for treating or preventing ophthalmic disease
CA2657164A1 (en) * 2006-07-27 2008-01-31 University Of Florida Research Foundation, Inc. Compositions and methods for treating or preventing ophthalmic light toxicity
JP2010525084A (ja) * 2007-04-26 2010-07-22 アミカス セラピューティックス インコーポレイテッド 薬理シャペロンを用いたリソソーム蓄積症治療のための投薬計画
US9999618B2 (en) 2007-04-26 2018-06-19 Amicus Therapeutics, Inc. Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones
CA2712593A1 (en) * 2008-02-01 2009-08-13 The Scripps Research Institute Methods for treating a condition characterized by dysfunction in protein homeostasis
US8321148B2 (en) * 2008-10-24 2012-11-27 Amicus Therapeutics, Inc. Multiple compartment dosing model
WO2010056746A1 (en) * 2008-11-11 2010-05-20 Amicus Therapeutics, Inc. Therapy regimens, dosing regimens and stable medicaments for the treatment of pompe disease
EP4212541A1 (en) 2008-12-16 2023-07-19 Genzyme Corporation Oligosaccharide-protein conjugates and their intermediates
CN106420740A (zh) * 2009-02-23 2017-02-22 伊莫根特病毒学有限责任公司 亚氨基糖以及治疗病毒性疾病的方法
EP2400843B1 (en) * 2009-02-24 2015-11-11 United Therapeutics Corporation Iminosugars and methods of treating arenaviral infections
US9206457B2 (en) * 2009-05-26 2015-12-08 Amicus Therapeutics, Inc. Utilization of pharmacological chaperones to improve manufacturing and purification of biologics
CA2763464C (en) * 2009-05-26 2018-11-06 Amicus Therapeutics, Inc. Utilization of pharmacological chaperones to improve manufacturing and purification of biologics
CA2765086C (en) 2009-06-12 2015-12-15 United Therapeutics Corporation Iminosugars and methods of treating bunyaviral and togaviral diseases
IN2012DN00352A (pt) * 2009-06-16 2015-08-21 Bikam Pharmaceuticals Inc
EP2459212B1 (en) 2009-07-28 2018-03-14 Shire Human Genetic Therapies, Inc. Compositions and methods for treating gaucher disease
CA2772875A1 (en) * 2009-09-04 2011-03-10 United Therapeutics Corporation Methods of treating orthomyxoviral infections
ES2485623T3 (es) * 2009-09-04 2014-08-13 United Therapeutics Corporation Procedimiento para el tratamiento de infecciones por poxvirus
ES2527623T3 (es) * 2009-09-04 2015-01-27 United Therapeutics Corporation Iminoazúcares para su uso en el tratamiento de enfermedades por filovirus
AR078498A1 (es) * 2009-10-01 2011-11-09 Baylor Res Inst Tratamiento de calvicie de patron masculino por induccion local del defecto metabolico de la enfermedad de fabry
HRP20211520T1 (hr) 2010-06-25 2021-12-24 Shire Human Genetic Therapies, Inc. Postupci i pripravci za dostavu iduronat-2-sulfataze u središnji živčani sustav
CN103179980B (zh) * 2010-06-25 2016-09-28 夏尔人类遗传性治疗公司 艾杜糖醛酸-2-硫酸酯酶的cns递送的方法和组合物
US20140219986A1 (en) * 2011-03-11 2014-08-07 Amicus Therapeutics ,Inc. Dosing regimens for the treatment of fabry disease
US20150258081A1 (en) * 2011-12-22 2015-09-17 Centogene Ip Gmbh Combination of a compound having the ability to rearrange a lysosomal enzyme and ambroxol and/or a derivative of ambroxol
CN104519905A (zh) 2012-03-02 2015-04-15 夏尔人类遗传性治疗公司 用于治疗iii型戈谢病的组合物和方法
KR20200032244A (ko) 2012-03-07 2020-03-25 아미쿠스 세라퓨틱스, 인코포레이티드 폼페병의 치료를 위한 고농도 알파-글루코시다제 조성물
US10155027B2 (en) 2012-07-17 2018-12-18 Amicus Therapeutics, Inc. Alpha-galactosidase A and 1-deoxygalactonojirimycin co-formulation for the treatment of fabry disease
US9694056B2 (en) 2012-07-17 2017-07-04 Amicus Therapeutics, Inc. α-galactosidase A and 1-deoxygalactonojirimycin co-formulation
WO2015009596A2 (en) * 2013-07-15 2015-01-22 New Yor University Methods and oral formulations for enzyme replacement therapy of human lysosomal and metabolic diseases
SI3201320T1 (sl) 2014-09-30 2024-02-29 Amicus Therapeutics, Inc. Zelo močna kislinska alfa-glukozidaza z okrepljenimi ogljikovimi hidrati
GB201508025D0 (en) 2015-05-11 2015-06-24 Ucl Business Plc Fabry disease gene therapy
PT3957320T (pt) 2015-12-30 2023-11-23 Amicus Therapeutics Inc Alfa-glicosidase ácida aumentada para o tratamento da doença de pompe
KR20230041833A (ko) 2015-12-30 2023-03-24 아미쿠스 세라퓨틱스, 인코포레이티드 폼페병 치료용의 강화된 산 알파-글루코시다제
KR20220145918A (ko) 2016-03-30 2022-10-31 아미쿠스 세라퓨틱스, 인코포레이티드 고 m6p 재조합 단백질의 선택 방법
US10512676B2 (en) 2016-03-30 2019-12-24 Amicus Therapeutics, Inc. Formulations comprising recombinant acid alpha-glucosidase
IL311121A (en) 2017-03-27 2024-04-01 Regeneron Pharma Sterilization method
JP7066157B2 (ja) 2017-06-14 2022-05-13 学校法人 明治薬科大学 ファブリー病治療用医薬の組合せ物及びその利用
US11590131B2 (en) 2017-07-28 2023-02-28 Applied Therapeutics, Inc. Compositions and methods for treating galactosemia
US20200316178A1 (en) * 2017-10-26 2020-10-08 Shire Human Genetic Therapies, Inc. Formulations comprising glucocerebrosidase and isofagomine
WO2020046132A1 (en) * 2018-08-31 2020-03-05 Leiden University Pharmacological chaperones for enzyme treatment therapy
NL2021840B1 (en) * 2018-10-19 2020-05-13 Univ Leiden Pharmacological Chaperones For Enzyme Treatment Therapy
EP3959196A4 (en) * 2019-04-25 2023-04-12 Takeda Pharmaceutical Company Limited ISOFAGOMIN SALTS, METHODS OF USE AND FORMULATIONS
SG11202111822QA (en) * 2019-05-07 2021-11-29 Univ Miami Treatment and detection of inherited neuropathies and associated disorders

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3607858A (en) * 1970-03-31 1971-09-21 American Cyanamid Co Process for preparing lyophilized human blood proteins such as gamma globulin in the presence of a nonionic surfactant
US4407957A (en) 1981-03-13 1983-10-04 Damon Corporation Reversible microencapsulation of a core material
US5879680A (en) 1987-12-23 1999-03-09 The United States Of America As Represented By The Department Of Health And Human Services Cloned DNA for synthesizing unique glucocerebrosidase
US6451600B1 (en) 1989-12-22 2002-09-17 Genzyme Corporation Enzymatically active recombinant glucocerebrosidase
US5236838A (en) 1988-12-23 1993-08-17 Genzyme Corporation Enzymatically active recombinant glucocerebrosidase
US5179023A (en) 1989-03-24 1993-01-12 Research Corporation Technologies, Inc. Recombinant α-galactosidase a therapy for Fabry disease
US5030638A (en) * 1990-02-26 1991-07-09 G. D. Searle & Co. Method of antiviral enhancement
US5139749A (en) 1990-06-22 1992-08-18 Tas, Inc. Fluidized calcining process
US5401650A (en) 1990-10-24 1995-03-28 The Mount Sinai School Of Medicine Of The City University Of New York Cloning and expression of biologically active α-galactosidase A
DK0585368T3 (da) 1991-04-25 1998-03-16 Univ Brown Res Found Implanterbart biokompatibelt immunisolatorisk vehikel til afgivelse af udvalgte terapeutiske produkter
DE69333955D1 (de) 1992-04-24 2006-02-02 Stanford Res Inst Int Targeting homologer sequenzen in eukaryotenzellen
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US5569189A (en) 1992-09-28 1996-10-29 Equidyne Systems, Inc. hypodermic jet injector
KR100291620B1 (ko) 1992-09-29 2001-10-24 추후제출 부갑상선호르몬의활성단편의폐를통한전달방법
US5250703A (en) * 1992-09-29 1993-10-05 Monsanto Company Pyrrolidin-3,4-diol derivatives of heptitols and preparation thereof
US5399567A (en) 1993-05-13 1995-03-21 Monsanto Company Method of treating cholera
US6291657B1 (en) 1993-05-13 2001-09-18 Monsanto Company Deoxygalactonojirimycin derivatives
US5798366A (en) 1993-05-13 1998-08-25 Monsanto Company Method for treatment of CNS-involved lysosomal storage diseases
AU686186B2 (en) 1993-05-27 1998-02-05 Aventisub Ii Inc. Topologically segregated, encoded solid phase libraries
FR2718357B1 (fr) 1994-04-06 1997-10-03 Defarges Alain Moreau Perfectionnements apportés à un dispositif d'injection par jet sans aiguille.
US5599302A (en) 1995-01-09 1997-02-04 Medi-Ject Corporation Medical injection system and method, gas spring thereof and launching device using gas spring
US5780014A (en) 1995-04-14 1998-07-14 Inhale Therapeutic Systems Method and apparatus for pulmonary administration of dry powder alpha 1-antitrypsin
US5654007A (en) 1995-06-07 1997-08-05 Inhale Therapeutic Systems Methods and system for processing dispersible fine powders
US20020013953A1 (en) 1995-08-02 2002-01-31 Reuser Arnold J. Compositions and methods for treating enzyme deficiency
US5916911A (en) 1995-09-20 1999-06-29 The Regents Of The University Of Michigan Amino ceramide--like compounds and therapeutic methods of use
US6458574B1 (en) 1996-09-12 2002-10-01 Transkaryotic Therapies, Inc. Treatment of a α-galactosidase a deficiency
US6083725A (en) 1996-09-13 2000-07-04 Transkaryotic Therapies, Inc. Tranfected human cells expressing human α-galactosidase A protein
US5948653A (en) 1997-03-21 1999-09-07 Pati; Sushma Sequence alterations using homologous recombination
US6210666B1 (en) 1997-10-21 2001-04-03 Orphan Medical, Inc. Truncated α-galactosidase A to treat fabry disease
EP1027069B1 (en) * 1997-10-29 2006-07-26 Genzyme Corporation Gene therapy for gaucher disease
US6274597B1 (en) * 1998-06-01 2001-08-14 Mount Sinai School Of Medicine Of New York University Method of enhancing lysosomal α-Galactosidase A
HUP0204199A3 (en) 1998-11-13 2005-09-28 Cyclacel Ltd Transport vectors
EP1137762B1 (en) 1998-12-07 2008-10-08 Genzyme Corporation Treatment of pompe's disease
ATE234626T1 (de) * 1999-07-26 2003-04-15 Searle & Co Verwendung von langkettigen n-alkyl derivaten von deoxynojirimycin mit glucocerebrosidase enzyme zur herstellung eines medikaments zur behandlung von mit glykolipiden akkumulation zusammenhängenden krankheiten
US6188045B1 (en) 2000-04-03 2001-02-13 Alto-Shaam, Inc. Combination oven with three-stage water atomizer
US20040204379A1 (en) 2000-06-19 2004-10-14 Cheng Seng H. Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
US20020095135A1 (en) * 2000-06-19 2002-07-18 David Meeker Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
US20020102329A1 (en) * 2000-07-22 2002-08-01 Michael Lanahan Methods for high-temperature hydrolysis of galactose-containing oligosaccharides in complex mixtures
US7001994B2 (en) * 2001-01-18 2006-02-21 Genzyme Corporation Methods for introducing mannose 6-phosphate and other oligosaccharides onto glycoproteins
WO2004037373A2 (en) 2002-10-21 2004-05-06 The Scripps Research Institute CHEMICAL CHAPERONES AND THEIR EFFECT UPON THE CELLULAR ACTIVITY OF β-GLUCOSIDASE
PT2444102E (pt) * 2003-01-31 2015-09-17 Sinai School Medicine Terapia combinada para o tratamento de distúrbios de deficiência proteica
WO2005077093A2 (en) 2004-02-06 2005-08-25 Biomarin Pharmaceutical Inc. Manufacture of highly phosphorylated lysosomal enzymes and uses thereof
EP3441090A1 (en) * 2005-05-17 2019-02-13 Amicus Therapeutics, Inc. A method for the treatment of pompe disease using 1-deoxynojirimycin and derivatives
JP2010525084A (ja) 2007-04-26 2010-07-22 アミカス セラピューティックス インコーポレイテッド 薬理シャペロンを用いたリソソーム蓄積症治療のための投薬計画

Also Published As

Publication number Publication date
BRPI0407001A (pt) 2006-01-10
EP2857036B1 (en) 2016-12-21
EP1589993A4 (en) 2007-09-26
US20060153829A1 (en) 2006-07-13
CA2514642A1 (en) 2004-08-19
CA2514642C (en) 2015-03-17
DK2332567T3 (en) 2015-07-13
CN1756558B (zh) 2012-04-25
HK1158955A1 (en) 2012-07-27
SI2857036T1 (sl) 2017-05-31
JP5875870B2 (ja) 2016-03-02
DK2444102T3 (en) 2015-07-13
CY1116463T1 (el) 2017-03-15
CA2814774A1 (en) 2004-08-19
EP3178486A1 (en) 2017-06-14
DK2441467T3 (en) 2015-08-31
JP2006516645A (ja) 2006-07-06
EP2444102A1 (en) 2012-04-25
CA2814767A1 (en) 2004-08-19
HK1169033A1 (en) 2013-01-18
ES2541952T3 (es) 2015-07-28
IL241315A (en) 2016-12-29
ES2619353T3 (es) 2017-06-26
SI1589993T1 (sl) 2015-05-29
CY1116215T1 (el) 2017-02-08
EP2444102B1 (en) 2015-04-08
MX344587B (es) 2016-12-20
EP2332567B1 (en) 2015-04-08
WO2004069190A2 (en) 2004-08-19
HK1207291A1 (en) 2016-01-29
JP2012102128A (ja) 2012-05-31
CY1116464T1 (el) 2017-03-15
US20040180419A1 (en) 2004-09-16
CN102580066A (zh) 2012-07-18
ES2531478T3 (es) 2015-03-16
EP2441467A1 (en) 2012-04-18
JP2012107020A (ja) 2012-06-07
PT2444102E (pt) 2015-09-17
EP2441467B1 (en) 2015-05-27
DK1589993T3 (en) 2015-03-09
SI2441467T1 (sl) 2015-10-30
CA2814774C (en) 2016-03-22
ES2545619T3 (es) 2015-09-14
IL241315A0 (en) 2015-11-30
HK1168778A1 (en) 2013-01-11
EP2332567A1 (en) 2011-06-15
MXPA05007822A (es) 2006-02-10
JP2016053071A (ja) 2016-04-14
US9597377B2 (en) 2017-03-21
EP1589993B1 (en) 2014-12-17
CN102586205A (zh) 2012-07-18
IL214441A0 (en) 2011-09-27
PT2441467E (pt) 2015-10-12
JP5589165B2 (ja) 2014-09-17
JP5808675B2 (ja) 2015-11-10
JP2011078413A (ja) 2011-04-21
HUE027113T2 (en) 2016-08-29
CN1756558A (zh) 2006-04-05
PT2857036T (pt) 2017-03-13
SI2332567T1 (sl) 2015-08-31
CY1118849T1 (el) 2018-01-10
HUE033381T2 (en) 2017-11-28
US20070178081A1 (en) 2007-08-02
US20180085437A1 (en) 2018-03-29
CY1116747T1 (el) 2017-03-15
EP2857036A1 (en) 2015-04-08
IL214440A0 (en) 2011-09-27
IL249389A0 (en) 2017-02-28
ES2541785T3 (es) 2015-07-24
CN102580067A (zh) 2012-07-18
SI2444102T1 (sl) 2015-08-31
DK2857036T3 (en) 2017-03-13
IL214439A0 (en) 2011-09-27
CA2814767C (en) 2016-03-15
ES2686775T3 (es) 2018-10-19
EP3178486B1 (en) 2018-06-06
IL214440A (en) 2017-03-30
PT1589993E (pt) 2015-03-04
WO2004069190A3 (en) 2005-06-23
JP6211573B2 (ja) 2017-10-11
IL169562A (en) 2016-04-21
EP1589993A2 (en) 2005-11-02

Similar Documents

Publication Publication Date Title
IL249389A0 (en) Combined therapy for the treatment of disorders associated with protein deficiency
IL169633A0 (en) Combination therapy for treating protein deficiencies
IL175055A0 (en) Combinations useful for the treatment of neuronal disorders
ZA200508427B (en) Methods for treating interleuking-6 related diseases
HK1092367A1 (en) Combination therapy for the treatment of ocular neovascular disorders
GB0201850D0 (en) Therapeutic treatment
GB0316912D0 (en) Therapeutic treatment
PL378108A1 (pl) Leczenie łączone do terapii zapalnych zaburzeń immunologicznych
GB0320806D0 (en) Therapeutic treatment
IL172249A0 (en) Methods for treating protein aggregation disorders
IL162818A0 (en) Combination therapy for the treatment of bacterialinfections
EP1646381A4 (en) COMBINED THERAPY FOR THE TREATMENT OF CHRONIC INFLAMMATORY DISEASES
GB0329275D0 (en) Therapeutic treatment
GB0307863D0 (en) Therapeutic treatment
ZA200505996B (en) Combination therapy for the treatment of immunoinflammatory disorders
GB0313772D0 (en) Therapeutic treatment
GB2397018B (en) Combination therapy for treating disease
GB0217271D0 (en) Therapeutic treatment for tinnitus
GB0321233D0 (en) Therapeutic treatment
GB0321650D0 (en) Therapeutic treatment
GB0321234D0 (en) Therapeutic treatment
GB0322000D0 (en) Therapeutic treatment
GB0318552D0 (en) Therapeutic treatment
GB0300881D0 (en) Therapeutic treatment
GB0321236D0 (en) Therapeutic treatment